ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,574.80
-1.17%
S&P ASX All Technology
2,961.30
-1.77%
Brent Oil
85.58
-0.37%
US Dollar vs AUD
1.54509
0.06%
Bitcoin
59,823.95
-1.28%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) News

LXRX Lexicon Pharmaceuticals Inc

1.56
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Lexicon Pharmaceuticals Inc LXRX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 1.56 09:57:00
Open Price Low Price High Price Close Price Previous Close
1.57 1.48 1.59 1.54 1.56
more quote information »

Recent News

Date Time Source Heading
29/4/202423:00GLOBELonnel Coats Retires as Chief Executive Officer and Board..
29/4/202421:00GLOBELexicon Pharmaceuticals to Host First Quarter 2024 Financial..
18/4/202422:00GLOBELexicon Pharmaceuticals to Host 2024 Investor Day
03/4/202423:00GLOBELexicon Pharmaceuticals to Participate in the 23rd Annual..
26/3/202400:20GLOBEClinical Data on the Impact of Sotagliflozin on Stroke and..
12/3/202423:00GLOBENew Post Hoc Analysis of inTandem3 Study Demonstrates..
12/3/202407:25EDGAR2Form PRE 14A - Other preliminary proxy statements
11/3/202422:26EDGAR2Form 8-K - Current report
11/3/202422:15GLOBELexicon Pharmaceuticals Reports Fourth Quarter..
11/3/202422:05GLOBELexicon Announces Oversubscribed $250 Million Private..
11/3/202422:00GLOBELexicon Preparing to Resubmit Sotagliflozin NDA for Type 1..
01/3/202408:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202408:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:00GLOBELexicon Pharmaceuticals Provides Business and Pipeline..
30/12/202309:29EDGAR2Form 8-K - Current report
30/12/202309:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/12/202308:04EDGAR2Form 8-K - Current report
22/12/202308:15GLOBELexicon Pharmaceuticals To Participate In The 42nd Annual..
30/11/202323:30GLOBELexicon Enrolls First Patient in Phase 2b Progress Study of..
22/11/202323:30GLOBELexicon Pharmaceuticals to Participate in the 35th Annual..
18/11/202308:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202309:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202306:10GLOBEINPEFA® (sotagliflozin) Use Associated With Early Clinical..
11/11/202308:01GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
09/11/202308:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202323:22EDGAR2Form 8-K - Current report
08/11/202323:00GLOBELexicon Pharmaceuticals Reports Third Quarter 2023 Financial..
04/11/202300:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2023 Financial..
03/11/202300:00GLOBEData on Early Clinical Benefit for INPEFA® (Sotagliflozin)..
02/11/202300:00GLOBEINPEFA® (Sotagliflozin) Receives Coverage From Express..
01/11/202307:01GLOBELexicon Strengthens Management Team With Two New Executives
31/10/202307:01GLOBENew Data Relating to Sotagliflozin to be Presented at the..
18/10/202307:01GLOBEData From Two Studies Demonstrating Positive Financial..
12/10/202307:06EDGAR2Form 8-K - Current report
12/10/202307:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202307:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/10/202300:00GLOBEData Demonstrating Financial Impact of INPEFA®..
10/10/202307:01GLOBEINPEFA® (Sotagliflozin) Receives Preferred Formulary Status..
09/10/202323:00GLOBETom Garner Joins Lexicon as Senior Vice President and Chief..
28/9/202323:00GLOBELexicon to Present Post Hoc Analysis of Scored Clinical..
26/9/202323:00GLOBELexicon to Present Study Results Relating to Sotagliflozin..

Your Recent History

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved